Dr. Slaoui had sat on the board of Moderna since 2017. Public officials, including Sen. Elizabeth Warren, D-Mass., have said his position with Moderna would have been a conflict of interest in his new role as head of COVID-19 vaccine development if he was incentivized to favor Moderna’s vaccine.
Moderna told Business Insider that Dr. Slaoui resigned from the board last week and that he will divest his $10 million in stock options.
Read the full article here.
More articles on pharmacy:
32 of 40 drugs deemed critical for COVID-19 in short supply
Gilead strikes deal to manufacture remdesivir for 127 countries
How Civica Rx has responded to drug shortages caused by COVID-19
